Buy generic drugs from our online pharmacy without prescription

0
You have no items in your shopping cart.

0

Welcome to our online store!

Buy Prandin online without prescription

Quick Overview

Prandin is used to stimulate insulin secretion from the pancreas in treatment of type 2 of diabetes mellitus.

Availability:
in stock
Product #:
000442
Active ingredient:
Repaglinide
Available Dosage:
0,5 mg;1 mg;2 mg;
Do I need a prescription?:
No, when purchased online
Payment options:
VISA, Mastercard, American Express, Diners Club, Jcb card and cryptocurrency (Bitcoin, Ethereum)
Delivery time:
Trackable Courier Service, 5-9 days, International Unregistered Mail, 14-21 days
Delivery to countries:
worldwide, including United Kingdom, Australia and USA

Prandin 0,5 mg Price

Package Price Per Pill  
30 pills x 0,5 mg $ 42.99 $ 1.43
60 pills x 0,5 mg $ 73.99 $ 1.23
90 pills x 0,5 mg $ 103.99 $ 1.16
120 pills x 0,5 mg $ 127.99 $ 1.07
180 pills x 0,5 mg $ 174.99 $ 0.97
360 pills x 0,5 mg
+Free International Unregistered Mail
$ 318.99 $ 0.89

Prandin 1 mg Price

Package Price Per Pill  
30 pills x 1 mg $ 47.99 $ 1.6
60 pills x 1 mg $ 76.99 $ 1.28
90 pills x 1 mg $ 103.99 $ 1.16
120 pills x 1 mg $ 124.99 $ 1.04
180 pills x 1 mg $ 167.99 $ 0.93
360 pills x 1 mg
+Free International Unregistered Mail
$ 302.99 $ 0.84

Prandin 2 mg Price

Package Price Per Pill  
30 pills x 2 mg $ 108.99 $ 3.63
60 pills x 2 mg $ 190.99 $ 3.18
90 pills x 2 mg
+Free International Unregistered Mail
$ 265.99 $ 2.96
120 pills x 2 mg
+Free International Unregistered Mail
$ 327.99 $ 2.73
180 pills x 2 mg
+Free International Unregistered Mail
$ 450.99 $ 2.51
360 pills x 2 mg
+Free International Unregistered Mail
$ 819.99 $ 2.28

Product information

In a study conducted by the Indian Institute of Health, Prandin treatment of type 2 of diabetes mellitus was found to be more effective in reducing blood glucose levels. A study conducted by Indian Academy of Medical Research (IAMR) has also found that Prandin treatment of type 2 of diabetes mellitus was superior to metformin in the treatment of type 2 of diabetes mellitus in patients with impaired glucose tolerance (IGT) or impaired glucose tolerance (IGTII) and patients with hyperglycemia (HGT). The study conducted by IAMR has also revealed that Prandin has beneficial effects on patients with type 1 diabetes mellitus. The study conducted by IAMR and Indian Institute of Medical Research (IIMR) has also revealed that Prandin treatment of type 2 of diabetes mellitus was superior to metformin in the treatment of type 2 of diabetes mellitus in patients with impaired glucose tolerance (IGT) or impaired glucose tolerance (IGTII) and patients with hyperglycemia (HGT). A randomized trial of Prandin (Pradiximab) and metformin (Pradixen) in type 2 diabetes and HGT Prandin is used to stimulate insulin secretion from the pancreas in treatment of type 2 of diabetes mellitus combined with a diet therapy and physical activities including combined treatment with metformin. Prandin is used to reduce the risk of type 2 of diabetes mellitus. Prandin is used to reduce the risk of type 2 of diabetes mellitus. Prandin can be used as a dietary supplement or to supplement diet alone. Prandin can be used as a dietary supplement or to supplement diet alone. Prandin can reduce the risk of type 2 of diabetes mellitus. Prandin may increase plasma levels of triglycerides, cholesterol and HDL. Prandin can be used for treatment of obesity or type 2. Prandin can be used for treatment of obesity or type 2. Prandin may be used to treat hypertension, type 2 diabetes, high blood pressure. Prandin may be added to diet to decrease blood levels of triglycerides, cholesterol and HDL in patients with type 2 diabetes mellitus. The following are products containing Prandin, but The study was designed to evaluate the effects of a Prandin-containing diet in type 2 diabetes with or without metformin therapy on blood glucose levels. RESULTS: Thirty-seven subjects (17 women and 16 men) were randomly assigned to follow a Prandin-containing diet in addition to the metformin therapy, either before, immediately after or at week 8 of treatment. There was no significant effect of diet on blood glucose levels at week 8. CONCLUSIONS: The results of this double-blind, placebo-controlled study support that Prandin-containing diet alone does not increase plasma insulin levels, while metformin does in patients with type 2 diabetes with or without type 2 diabetes. A total of 3 trials were performed using Prandin and a diet therapy for diabetes. The trials used different dosage ranges of Prandin. The trial using a higher dose of Prandin was a double blind placebo controlled trial with a 6 month follow up. The trial using a lower dose of Prandin was a double blind controlled trial with a 7 month follow up. Results of the trials showed that the overall response time for Prandin was faster than the control treatment with metformin. There was a significant decrease in the percentage of response with the lower dosage. Prandin treatment also resulted in a significant improvement in the glycosylated hemoglobin (HbA2c) level in patients with type 2 diabetes. The trial using a low dose of Prandin resulted in significant reduction in total insulin levels of patients with type 2 diabetes. However, these results showed that there was no statistically significant difference in the percentage of response with the low dose. The trial using a high dose of Prandin resulted in a significant improvement in the percentage of response with the high dose. However, this trial also showed that the response with the high dose was not statistically significant. There is currently no approved treatment for type 2 diabetes in India. In this study, the primary objective was to investigate the effects of a diet containing 10% Prandin and metformin on fasting plasma glucose and serum insulin, fasting C-peptide, plasma insulin and serum insulin and C-peptide levels after 12 h of Prandin treatment. Plasma insulin and serum insulin levels were also examined at 24, 48 and 72 h. After 24 h fasting, there was a significant decrease in fasting plasma glucose and serum insulin levels, as well as a decrease in total C-peptide concentration (P< 0.05), and the concentration of total C-peptide was reduced by a significant amount (P < 0.05). There was a significant reduction in fasting serum insulin and C-peptide after 24 h treatment of Prandin. After 48 h treatment, the concentrations of fasting C-peptide and serum insulin did not change significantly. The reduction in fasting plasma glucose and serum insulin concentrations and decrease in C-peptide level did not occur in a combination treatment with metformin and prandin. These results indicate that Prandin treatment is able to reduce C-peptide levels and decrease fasting plasma glucose levels in type 2 patients.
More info loading...